Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Daniel Maslyar
Introduction
Daniel Maslyar is an accomplished inventor based in San Carlos, California. He has made significant contributions to the field of cancer treatment through his innovative research and patent.
Latest Patents
Maslyar holds a patent for the "Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment." This invention relates to methods and kits that assess the responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. The methods include measuring the level of HE4 expression in a sample from a subject and comparing it with previous samples. This groundbreaking work has the potential to enhance cancer treatment strategies.
Career Highlights
Daniel Maslyar is associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to medicine. His work at Genentech has allowed him to contribute to advancements in cancer therapies and improve patient outcomes.
Collaborations
Maslyar has collaborated with notable colleagues, including Mark Lackner and Yulei Wang. These partnerships have fostered a collaborative environment that encourages innovation and the development of new therapeutic strategies.
Conclusion
Daniel Maslyar's contributions to cancer treatment through his patent and work at Genentech highlight his role as a significant innovator in the field. His research continues to pave the way for advancements in medical science.